Natera, Inc. Common Stock (NTRA) Stock Price
NTRAStock
$393.44+117.92%52W
Market Cap$56.71B
P/E—
PEG Ratio—
Div yield—
Beta1.54
NTRA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)73.40%
Price vs S&P 500 (4W)7.48%
VGM Score60.09
NTRA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.53 | -$0.47 | +11.99%(+$0.06) | |
| Q1 2026 | -$0.55 | -$0.60 | -8.52%(-$0.05) | |
| Q4 2025 | -$0.53 | $0.36 | +167.46%(+$0.89) | |
| Q3 2025 | -$0.35 | -$0.64 | -80.73%(-$0.29) | |
| Q2 2025 | -$0.59 | -$0.74 | -24.54%(-$0.15) |
NTRA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.30
4.27
4.27
4.27
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About Natera, Inc. Common Stock
Natera provides molecular diagnostic tests across reproductive health, oncology, and transplantation. Its main products include Panorama for non-invasive prenatal screening, Horizon for genetic carrier assessment, Signatera for circulating tumor DNA detection in cancer monitoring, and Prospera for organ transplant rejection assessment. The company leverages proprietary molecular and bioinformatics technology across these applications.